ATEC

Business Context and Reporting Period

Company: Alphatec Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Alphatec designs, develops, manufactures, and markets spinal surgery implants. The company operates primarily in the United States and Japan. In June 2006, the company completed an Initial Public Offering (IPO), raising approximately $70.2 million in net proceeds. The financial statements reflect the company as a "Successor" entity following its acquisition of Alphatec Spine, Inc. in March 2005.

Key Financial Metrics

Note: Net Loss Applicable to Common Stockholders includes accretion to the redemption value of redeemable convertible preferred stock.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 133% ($11.1 million) for the three months ended June 30, 2006, compared to the same period in 2005. For the six months, revenue increased 146% ($22.3 million). Growth was driven by expanded sales networks in the U.S. and Japan, and the inclusion of Cortek, Inc. (acquired Sept 2005) results.
• Operating Expenses: Total operating expenses increased significantly due to higher sales commissions, hiring of additional personnel, and costs associated with the IPO and public company compliance. General and administrative expenses rose $5.0 million (Q3) and $9.9 million (YTD) compared to prior year periods.
• Liquidity: Cash and cash equivalents increased from $2.2 million at December 31, 2005, to $25.0 million at June 30, 2006, primarily due to net proceeds from the IPO ($70.2 million).
• Debt Structure: The company repaid a $3.0 million related-party note and reduced borrowings under its revolving credit facility using IPO proceeds. However, new term loans of approximately $2.7 million were entered into with GE Capital Corporation in Q2 2006.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management anticipates continuing to incur net losses for the foreseeable future as it invests in sales, marketing, and R&D. The company believes current cash and credit facilities are sufficient to fund operations through 2007.
• Unusual Items:
  • Stock-Based Compensation: The company adopted SFAS No. 123(R) effective Jan 1, 2006, resulting in $3.5 million of stock-based compensation expense for the six months ended June 30, 2006.
  • Acquisition Costs: The six-month 2005 period included a $3.1 million non-cash write-off of in-process research and development (IPR&D) related to the Alphatec Spine acquisition, which is not present in the 2006 period.
• Risks and Contingencies:
  • Patent Litigation: Biedermann Motech GmbH and Depuy Spine filed a patent infringement suit (U.S. Patent No. 5,207,678) in June 2006, seeking a preliminary injunction against the sale of Zodiac and Solanas products. Alphatec has filed counterclaims.
  • Royalty Dispute: Four surgeons filed a complaint in April 2006 claiming entitlement to 6% royalties on polyaxial screw sales. The matter is in mediation.
  • Internal Controls: The company identified a material weakness in internal controls over financial reporting as of Dec 31, 2005, related to the year-end close process and staffing. Remediation efforts are underway.
  • Supply Chain: Reliance on a single source supplier (Invibio) for PEEK material used in 14.1% of revenue-generating products.

Investor Verification Checklist

• Patent Litigation Status: Verify the outcome of the preliminary injunction motion filed by Biedermann Motech/Depuy regarding the Zodiac and Solanas products, as this could halt sales of key revenue drivers.
• Internal Control Remediation: Confirm the progress of remediation for the material weakness in internal controls identified by the independent auditors to ensure future financial reporting reliability.
• Debt Covenants: Review compliance with debt covenants under the Bank of the West and GE Capital facilities, specifically regarding net loss limits and profitability ratios, given the company's current unprofitable status.
• Supplier Concentration: Assess the risk associated with the single-source supply of PEEK material and the availability of human tissue for allograft products.
• Redeemable Preferred Stock: Understand the terms of the $23.7 million New Redeemable Preferred Stock issued during the IPO and its impact on future cash flows and equity dilution.